What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Tislelizumab will be administered every 3 weeks Intravenous infusion on day 1 of each cycle.”In the company’s words, NCT06206733 on ClinicalTrials.gov
- Tested for
- Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Cancer (GC)
- Main trialPhase 3
- “This study is a multicenter, randomized, double-blind, standard-of-care controlled phase III clinical study conducted in China. The purpose of this study is to evaluate the efficacy of ASKB589 plus CAPOX and PD-1 inhibitor compared with placebo plus CAPOX and PD-1 inhibitor (as first-line treatment) as measured by Progression Free Survival (PFS).”In the company’s words, NCT06206733 on ClinicalTrials.gov
Other drugs for Gastroesophageal Junction Adenocarcinoma
- CAM2029Camurus AB · Phase 3
- Disitamab VedotinRemeGen · Phase 3
- RYZ101RayzeBio, Inc. · Phase 3
- ZanidatamabJazz Pharmaceuticals · Phase 3
- M108FutureGen Biopharmaceutical (Beijing) Co., Ltd · Phase 3
- RilvegostomigAstraZeneca · Phase 3
Coming up1
- 30 DecPhase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 30 Dec 2026 | ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma | |
| Phase 1/2Active, not recruiting | 31 Oct 2025 | ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026